Sun Pharma Advanced Research Company Limited (SPARC) fair value: what the stock is really worth
As of Oct 28, 2026: fair value (intrinsic value) of Sun Pharma Advanced Research Company Limited stock ₹522, price ₹183, upside +185.8%, quality 60 out of 100. Rating: strongly undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Oct 27, 2026.
How to read this chart
60‑month range ₹108.71 – ₹455.30 · fair‑value band ₹346.74 – ₹844.94 · the ₹182.66 price screens below the ₹522.12 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Oct 27, 2026.
Follow Sun Pharma Advanced Research Company in your weekly email
Every Wednesday you see whether Sun Pharma Advanced Research Company is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Sun Pharma Advanced Research Company Limited, a clinical-stage biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops products with a therapeutic focus on oncology and immunology.
Show moreShow less
The company is also developing Vodobatinib (SCO-088), a BCR-ABL inhibitor, for the treatment of refractory chronic myelogenous leukemia that is in phase 2 clinical trial; and Vibozilimod (SCD-044), a selective sphingosine-1-phosphate receptor 1 (S1PR1) agonist, for the treatment of psoriasis and atopic dermatitis that is in phase 2 clinical trial.
In addition, it develops SCD-153 for the treatment of alopecia areata; and SBO-154, an anti-MUC-1 ADC, for the treatment of multiple tumors that is in preclinical trials. The company was incorporated in 2006 and is based in Mumbai, India.
Stock analysis
Sun Pharma Advanced Research Company Limited (SPARC) currently trades at ₹182.66, while our model-based Fair Value estimate is ₹522.12, implying the stock looks roughly 65.0% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ₹2,224 per share, and 12 of the 15 models we run sit above the ₹182.66 price.
Bear case: the Multiples group reads lowest at ₹202.67, and 3 of the 15 models stay below the price. Data coverage for this calculation is medium.
Scenario range: ₹346.74 (bear) to ₹844.94 (bull), the price of ₹182.66 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 60/100 (solid quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Sun Pharma Advanced Research Company Limited reported revenue of ₹18.8B in FY2026 versus ₹1.4B in FY2022, a compound +92.4%/yr. Reported net income was ₹15.5B in FY2026.
Key figures
Market cap ₹59.3B (≈ $623M) Small · P/E ratio 3.7 · P/S ratio 3.10 · EPS (TTM) ₹48.81 · Net margin 83.0% · Return on equity 277% · Return on assets (EBIT) −37.4% · Operating margin −90.7%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 54 out of 100 (medium confidence).
What moves the price
The share trades about 34% below its 52-week high and 68% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −24% fair-value upside, at 186%, SPARC screens cheaper than that median.
Fair Value models
Bear₹346.74Fair Value ₹522.12Bull₹844.94
Price ₹182.66 · Upside +185.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 7 months old). Earnings retained since then (₹28.35 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+2,518.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+98.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+49.3%
Start year 2021 (pandemic). Over 10 years: +27.8% a year
Revenue growth 19 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+58.2%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−57.7% (2021) → 84.5% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
Compare Sun Pharma Advanced Research Company Limited with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 579 stocks
Beats the industry median on 8/11 measures
Overall it ranks above its industry peers.
Valuation
Quality Score60 · Above median
Fair Value upside+185.8% · Top 25%
Profitability
Return on equity (12 months)276.9% · Top 25%
Return on assets71.6% · Top 25%
Net margin (12 months)83.0% · Top 25%
Operating margin (12 months)−90.7% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)314.1% · Top 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Sun Pharma Advanced Research Company Limited Fair Value". https://www.fairvalue-calculator.com/stock/SPARC
Frequently asked questions
Is Sun Pharma Advanced Research Company Limited (SPARC) overvalued or undervalued?
As of Oct 27, 2026, our model estimates a fair value of ₹522.12 versus a price of ₹182.66, about +186% upside (undervalued).
What is the fair value of SPARC?
Our model-based fair value for Sun Pharma Advanced Research Company Limited is ₹522.12 (as of Oct 27, 2026), built from audited fundamentals. The current price: ₹182.66.
What is the quality score of SPARC?
Sun Pharma Advanced Research Company Limited has a Quality Score of 60/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Sun Pharma Advanced Research Company Limited (SPARC)?
Our model-based price target is the fair value of ₹522.12 (as of Oct 27, 2026) from 15 valuation models. Cautious scenario ₹346.74, optimistic scenario ₹844.94. It is a calculation from audited fundamentals, not an analyst target.
What is the Sun Pharma Advanced Research Company Limited stock forecast for 2026?
Our models put fair value at ₹522.12, about +186% upside versus a price of ₹182.66 (undervalued). Cautious scenario ₹346.74, optimistic scenario ₹844.94. The calculation is refreshed regularly with new filings.
What is the revenue of Sun Pharma Advanced Research Company Limited (SPARC)?
Sun Pharma Advanced Research Company Limited reported trailing-twelve-month revenue of about ₹19.1B (latest available figure, as of Oct 27, 2026).
What is the intrinsic value of Sun Pharma Advanced Research Company Limited (SPARC)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Sun Pharma Advanced Research Company Limited it is ₹522.12 per share (as of Oct 27, 2026), against a price of ₹182.66. It is the blended result of 15 valuation models (cash flow, earnings, asset, dividend).
Is Sun Pharma Advanced Research Company Limited stock overvalued or undervalued in 2026?
As of Oct 27, 2026, SPARC trades below its calculated fair value: price ₹182.66, fair value ₹522.12, a gap of about +186% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SPARC?
No. The price is what the market pays today (₹182.66); the fair value is what the company's own numbers justify (₹522.12). For Sun Pharma Advanced Research Company Limited the two are ₹339.46 per share apart. That gap is exactly why we show both numbers side by side.
How much is Sun Pharma Advanced Research Company Limited worth?
The market values Sun Pharma Advanced Research Company Limited at about ₹59.3B (market capitalisation, as of Oct 27, 2026). Per share that is ₹182.66; our models calculate a fair value of ₹522.12 per share.
What do the bullish and bearish scenarios say about SPARC?
Our models span a range for Sun Pharma Advanced Research Company Limited: cautious scenario ₹346.74, base ₹522.12, optimistic ₹844.94 per share (as of Oct 27, 2026, price ₹182.66). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of SPARC?
Sun Pharma Advanced Research Company Limited trades at a price-to-earnings ratio of 3.7 (as of Oct 27, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹522.12 is built from several models across several years. Other multiples: P/B 4.4, P/S 3.1, EV/EBITDA 3.7.
How solid is the balance sheet of Sun Pharma Advanced Research Company Limited (SPARC)?
Balance-sheet figures for Sun Pharma Advanced Research Company Limited (as of Oct 27, 2026): return on equity 276.9%. They feed the Quality Score of 60/100, which measures business quality independently of the share price.
How far is SPARC from its 52-week high?
Sun Pharma Advanced Research Company Limited trades at ₹182.66, about 34% below its 52-week high of ₹277.57 and 68% above the low of ₹108.71 (as of Oct 28, 2026). Distance from the high says nothing about value: that is what the fair value of ₹522.12 is for.
Which stocks are comparable to Sun Pharma Advanced Research Company Limited?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Sun Pharma Advanced Research Company Limited stock attractive at the current price?
The data as of Oct 27, 2026: price ₹182.66, calculated fair value ₹522.12 (+186%), Quality Score 60/100, from 15 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of SPARC calculated?
We run Sun Pharma Advanced Research Company Limited through 15 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹522.12, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.4 % above its aggregate fair value. Sun Pharma Advanced Research Company Limited currently trades 65 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Sun Pharma Advanced Research Company Limited (SPARC)?
The closing price on Oct 28, 2026 was ₹182.66. Our model-based fair value is ₹522.12, about +186% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Sun Pharma Advanced Research Company Limited right now?
The price is below even our cautious bear case (₹346.74). The market is more pessimistic than our downside scenario. Solid quality (60/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (₹346.74 to ₹844.94) leaves room in how you read the outcome.
Key figures of Sun Pharma Advanced Research Company Limited
How large is the market capitalisation of Sun Pharma Advanced Research Company Limited (SPARC)?
The market capitalisation of Sun Pharma Advanced Research Company Limited is ₹59.3B (≈ $623M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Sun Pharma Advanced Research Company Limited (SPARC)?
The price-to-sales ratio of Sun Pharma Advanced Research Company Limited is 3.10 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Sun Pharma Advanced Research Company Limited (SPARC)?
Earnings per share at Sun Pharma Advanced Research Company Limited are ₹48.81 (price ÷ EPS = P/E 3.7). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Sun Pharma Advanced Research Company Limited (SPARC)?
The net margin of Sun Pharma Advanced Research Company Limited is 83.0% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Sun Pharma Advanced Research Company Limited (SPARC)?
The return on equity (ROE) of Sun Pharma Advanced Research Company Limited is 277% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Sun Pharma Advanced Research Company Limited (SPARC)?
On an EBIT basis the return on assets of Sun Pharma Advanced Research Company Limited is −37.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Sun Pharma Advanced Research Company Limited (SPARC)?
The operating margin of Sun Pharma Advanced Research Company Limited is −90.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Sun Pharma Advanced Research Company Limited (SPARC)?
Revenue at Sun Pharma Advanced Research Company Limited is growing +314% versus a year earlier (3y avg +98.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Sun Pharma Advanced Research Company Limited (SPARC) generate?
The free cash flow of Sun Pharma Advanced Research Company Limited is −₹3.0B (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Sun Pharma Advanced Research Company Limited (SPARC) carry?
The net debt of Sun Pharma Advanced Research Company Limited is ₹5.6B (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Sun Pharma Advanced Research Company Limited in the live analysis
One click puts Sun Pharma Advanced Research Company Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.
Some data
Oct 27, 2026